Close Menu

UPenn

The phase III trial saw significant overall survival and remission rates in relapsed or treatment refractory acute myeloid leukemia cases treated with the FLT3 inhibitor gilteritinib.

A modified analogue of rucaparib is being used to track PARP-1 expression in PARP inhibitor-treated patients with pancreatic, breast, prostate, and other cancer types.

Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.

Maintenance treatment with Clovis' rucaparib may be a more tolerable maintenance therapy than chemo in platinum-responsive patients with mutations in BRCA1/2 or PALB2.